Our Privacy Statment & Cookie Policy
All LSEG websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
This week has brought news of promising results from several clinical trials. A study published in The Lancet on Monday revealed that a vaccine, jointly developed by Oxford University and AstraZeneca, had performed well in the first phase of testing, producing a dual immune response in its patients (T-cells within 14 days of vaccination and antibodies after 28 days). Another study, based in China and also covered by the Lancet article, had similar results. Meanwhile, shares in respiratory drug developer Synairgen gained more than 400% following news that its inhalation treatment reduced the likelihood of developing severe symptoms in COVID-19 patients by almost 80%.
Refresh this chart in your browser | Edit the chart in Datastream
This chart is taken from Fathom’s Recovery Watch newsletter. Click here to subscribe to Recovery Watch and Forums.
Next forum date: Monday 27 July 2020
__________________________________________________________________________________
Financial time series database which allows you to identify and examine trends, generate and test ideas and develop view points on the market.
Refinitiv offers the world’s most comprehensive historical database for numerical macroeconomic and cross-asset financial data which started in the 1950s and has grown into an indispensable resource for financial professionals. Find out more.
There is a paradox in the state of the US economy that is creating something of a ...
The Chicago Board of Exchange’s volatility index, simply known as VIX, flickered into ...
Developed markets are gradually converging towards their old, pre-COVID economic trends ...
U.S. retail sales smashed expectations in March, with total sales (mkt +0.3% m/m) up ...